As of close of business last night, Abbott Laboratories’s stock clocked out at $113.16, up 0.64% from its previous closing price of $112.44. In other words, the price has increased by $+0.72 from its previous closing price. On the day, 8298605 shares were traded.
Ratios:
To gain a deeper understanding of ABT’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 26.98 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 38.81. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.64. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.38.
On May 30, 2023, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight but kept the price unchanged to $112.
Wolfe Research reiterated its Underperform rating for the stock on April 20, 2023, while the target price for the stock was revised from $107 to $103.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 01 ’24 when Salvadori Daniel Gesua Sive sold 963 shares for $118.50 per share. The transaction valued at 114,116 led to the insider holds 125,697 shares of the business.
ALLEN HUBERT L sold 853 shares of ABT for $101,080 on Mar 01 ’24. The EXECUTIVE VICE PRESIDENT now owns 184,806 shares after completing the transaction at $118.50 per share. On Mar 01 ’24, another insider, Morrone Louis H., who serves as the EXECUTIVE VICE PRESIDENT of the company, sold 801 shares for $118.50 each. As a result, the insider received 94,918 and left with 62,968 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABT now has a Market Capitalization of 195.10B and an Enterprise Value of 203.45B. As of this moment, Abbott’s Price-to-Earnings (P/E) ratio for their current fiscal year is 34.65, and their Forward P/E ratio for the next fiscal year is 21.99. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.44. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.90 while its Price-to-Book (P/B) ratio in mrq is 5.08. Its current Enterprise Value per Revenue stands at 5.07 whereas that against EBITDA is 19.30.
Stock Price History:
Over the past 52 weeks, ABT has reached a high of $121.64, while it has fallen to a 52-week low of $89.67. The 50-Day Moving Average of the stock is 115.39, while the 200-Day Moving Average is calculated to be 106.12.
Shares Statistics:
It appears that ABT traded 5.24M shares on average per day over the past three months and 7M shares per day over the past ten days. A total of 1.73B shares are outstanding, with a floating share count of 1.72B. Insiders hold about 0.73% of the company’s shares, while institutions hold 77.12% stake in the company. Shares short for ABT as of Feb 29, 2024 were 14.92M with a Short Ratio of 2.85, compared to 12.7M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.86% and a Short% of Float of 0.86%.
Dividends & Splits
With its trailing 12-month dividend rate of 2.08, ABT has a forward annual dividend rate of 2.08. Against a Trailing Annual Dividend Yield of 1.85%, it implies a Forward Annual Dividend Yield of 1.94%. The stock’s 5-year Average Dividend Yield is 1.58. The current Payout Ratio is 63.81% for ABT, which recently paid a dividend on May 15, 2024 with an ex-dividend date of Apr 12, 2024. Stock splits for the company last occurred on Jan 02, 2013 when the company split stock in a 10000:4798 ratio.
Earnings Estimates
As of right now, 20 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0.96 for the current quarter, with a high estimate of $1.01 and a low estimate of $0.94, while EPS last year was $0.94. The consensus estimate for the next quarter is $1.12, with high estimates of $1.21 and low estimates of $1.09.
Analysts are recommending an EPS of between $4.89 and $4 for the fiscal current year, implying an average EPS of $4.61. EPS for the following year is $5.09, with 24 analysts recommending between $5.36 and $4.39.
Revenue Estimates
In the current quarter, 18 analysts expect revenue to total $9.89B. It ranges from a high estimate of $10.17B to a low estimate of $9.77B. As of the current estimate, Abbott Laboratories’s year-ago sales were $8.91B, an estimated increase of 11.00% from the year-ago figure. For the next quarter, 18 analysts are estimating revenue of $10.49B, an increase of 8.10% less than the figure of $11.00% in the same quarter last year. There is a high estimate of $10.63B for the next quarter, whereas the lowest estimate is $10.36B.
A total of 25 analysts have provided revenue estimates for ABT’s current fiscal year. The highest revenue estimate was $42.53B, while the lowest revenue estimate was $41.74B, resulting in an average revenue estimate of $42B. In the same quarter a year ago, actual revenue was $40.11B, up 4.70% from the average estimate. Based on 24 analysts’ estimates, the company’s revenue will be $44.99B in the next fiscal year. The high estimate is $45.75B and the low estimate is $44.19B. The average revenue growth estimate for next year is up 7.10% from the average revenue estimate for this year.
